Wheather or not a large premium is possible, deserved or likely was not my point. PH20/regular insulin could be best in class fast acting insulin, sell for less than brand analogs and make huge profits. PH20/analog could sell at competitive prices and still make a good profit. To assume a large premium is necessary for HALO to make good profits is misguided imo. If significant health benifits are achieved, I expect a premium will be charged but not out of the necessity of increased base cost for drug. If I need to clarify my thinking, I will.
Market Data 
Markets 
AI
